Skip to main content
Erschienen in: BMC Psychiatry 1/2018

Open Access 01.12.2018 | Case report

Persistent catatonia following epileptic seizures: a case report and systematic literature search

verfasst von: Ragnar Verbraeken, Jurjen J. Luykx

Erschienen in: BMC Psychiatry | Ausgabe 1/2018

Abstract

Background

Catatonia is frequently associated with mood and psychotic disorders as well as with general medical conditions, especially with seizures. In the case of the latter, catatonia mostly resolves when the seizures respond to the anticonvulsive treatment. We report, to our knowledge, the first case of a patient without affective or psychotic disorder, who developed catatonia in the postictum and whose catatonia did not resolve with anticonvulsive treatment, but did so with lorazepam.

Case presentation

We describe a 36-year-old man, with no psychiatric history, except for a possible disorder in the use of cannabis, who developed catatonia after epileptic seizures. The catatonia did not respond to the anticonvulsant therapy, but did so to lorazepam 17 mg/d. Lorazepam could be tapered slowly and stopped without reemergence of catatonic signs.

Conclusion

Catatonia should be part of the differential diagnosis in patients with bradyphrenia and/or remarkable postictal behavior. This report shows that lorazepam should be taken into consideration (before moving to ECT), in cases of unresolved catatonia, even if the seizures are reduced with anticonvulsants.
Abkürzungen
AED
Anti-epileptic drugs
BFCRS
The Bush Francis catatonia rating scale
CAT Scan
Computer Assisted Tomography
CK
Creatinine kinase
CRP
C-reactive protein
dd
Daily dose
DSM-5
5th edition of Diagnostic and Statistical Manual of Mental Disorders
ECT
Electroconvulsive therapy
EEG
Electroencephalogram
ES
Epileptic seizures
GABAA
Gamma-aminobutyric acid A
MRI
Magnetic resonance imaging
NMDA
N-methyl D-aspartate
OCD
Obsessive compulsive disorder
PNES
Psychogenic non-epileptic seizures
U/L
Units per liter

Summary

We describe the first case of persistent catatonia following an epileptic seizure (ES) of a patient without a history of psychotic or affective disorders. The catatonic symptoms did not go into remission until a dose of lorazepam 17 mg daily was reached. We tapered and finally discontinued lorazepam without the patient developing new signs of catatonia.

Background

Catatonia is a psychomotor symptom cluster first described by C. Wernicke (motility psychosis) and by K.L. Kahlbaum in 1874 in his publication ‘Die Katatonie oder das Spannungsirresein’ in which he regarded ‘being extremely tense’ as the main characteristic of catatonia [1]. Catatonia is observed in a plethora of psychiatric disorders, primarily mood and psychotic disorders, but sometimes in cases of, for example, autism [25] or obsessive compulsive disorder (OCD) [6] as well. In DSM-5 it has become possible to classify catatonia as ‘catatonia as specifier’ or ‘catatonic disorder not otherwise specified’ or ‘unspecified catatonia’. Furthermore, catatonia also occurs in non-psychiatric disorders such as neurological disorders, in metabolic diseases and intoxications, as a consequence of medication [5, 79], postoperatively [5], or after withdrawal of alcohol [10], benzodiazepines [8] or cannabis [11]. To our knowledge, catatonia following an ES had not been described before the current report. Here, by describing a case and a systematic literature search we raise awareness of this possible postictal condition to enable earlier diagnosis and management.

Case presentation

A 38- year-old man, with no psychiatric history, known to suffer from epilepsy but who stopped his antiepileptic drugs (AED) is brought into a community hospital’s emergency room by an ambulance after being found in the streets in a confused condition and with reduced awareness. The history taking in the emergency room is hampered by bradyphrenia and amnesia. The patient merely relates a vague account of a pub fight. At that instant he does not know where he lives nor is he able to provide any contact information about relatives or friends. General physical examination, neurological examination, urine toxicology, brain CAT and cerebrospinal fluid findings (proteins and cells, mainly to exclude meningitis/encephalitis) are unremarkable. Blood analysis shows slight signs of leukocytosis. The EEG shows general slowing without traces of epilepsy. The patient is admitted to the neurology department for diagnostic work-up.
The next day the patient is somewhat less slow and more aware, although still unaware of the events on the day prior to admission. He believes to have fallen as a consequence of an ES. He indicates he has not been taking his AED for some time. Valproic acid was therefore restarted at a dose of 1500mgs daily. He denies having used any drugs or alcohol, as confirmed by urine toxicology. A new blood analysis is carried out, showing a decrease in leukocytosis, an increase of CK to 521 U/L and a slight increase in CRP to 16.2 mg/L. Brain MRI is unremarkable.
Two days after his admission an ES is observed by nursing staff and is interpreted as tonic-clonic, generalized. No clear underlying cause is identified. Valproic acid blood levels are 54 mg/L (at the time of admission this was < 10 mg/L), leading us to increase the dose to 2x1000mg/d. The EEG is unchanged.
The patient then shows peculiar behaviour: he stares and speaks little, leading the neurologist to suspect a psychotic episode and therefore a psychiatrist is consulted. During the psychiatric history the patient informs him that he does not have any complaints other than noticing being somewhat slow. He himself attributes this to the restarted AED. During psychiatric examination we notice bradyphrenia. The patient does blink his eyes and moves slowly, though fluently. There is no posturing or grimacing. He is friendly and cooperative. His conscienceness is clear and his attention span is undisturbed. He is well-oriented. Perception, memory and mood appear intact. The affect is flattened. He denies having suicidal thoughts.
Given this symptomatology the differential diagnosis at that stage included side effects of the valproic acid and, although there were insufficient DSM-5 criteria for catatonia at the time, catatonia. The attending psychiatrist decided to re-evaluate the patient a few days later.
Upon that re-evaluation, the patient rubs his hands in a stereotypical manner and there is evidence of grimacing and posturing (the patient sits bent over for minutes, with hands, head and shoulders in the same position) and of ambitendency. There is no Gegenhalten, no negativism, no Mitmachen. The Bush Francis catatonia rating scale (BFCRS) scores: 0 1 0 1 2 1 0 2 0 0 0 0 0 0 2 0 0 0 3 0 0 0 0 = 12 (Table 1). Again, the EEG remains without abnormalities and unchanged. Given the stereotypies, the bradyphrenia, hypoactivity, inappropriate behaviour, ambitendency and posturing combined with a BFCRS score of 12, we concluded the patient was suffering from postictal catatonia becoming more severe within 8 days following a seizure. To confirm this hypothesis, we treated him with lorazepam 3dd1mg and 1dd2.5 mg, without improvement, but the lorazepam didn’t bring about any sedation. He was then transferred to the psychiatry department for further diagnostic work-up and treatment. During the first days of his stay at the ward symptoms and signs were unchanged. A fourth EEG showed no change either. Lorazepam was increased by 3 mg every 2 days until at a total dose of 17 mg/d the patient clearly improved: he became more talkative, started moving more fluently and has not shown signs of grimacing or posturing since. His mood has remained cheerful. Then, lorazepam was gradually tapered by 1 mg/d until it could be stopped completely, with the patient remaining stable and free of symptoms. On his day of discharge at 0 mg of lorazepam an EEG showed a normal base rhythm with only a couple of short episodes of general slowing.
Table 1
Overview of the catatonic features during the course of illness. Day numbers refer to the number of days after the epileptic seizure
 
Day 8 (0 mg Lorazepam)
Day 12 (11.5 mg Lorazepam)
Day 16 (17 mg Lorazepam)
Day33 (0 mg Lorazepam
Excitement
0
0
0
0
Immobility/stupor
1
1
0
0
Mutism
0
0
0
0
Staring
1
1
0
0
Posturing/catalepsy
2
1
0
0
Grimacing
1
1
0
0
Echopraxie/echolalia
0
0
0
0
Strereotypy
2
1
0
0
Mannerisms
0
0
0
0
Verbigeration
0
0
0
0
Rigidity
0
0
0
0
Negativism
0
0
0
0
Waxy flexibility
0
0
0
0
Withdrawal
0
0
0
0
Impulsivity
2
1
0
0
Autonomic obedience
0
0
0
0
Mitgehen
0
0
0
0
Gegenhalten
0
0
0
0
Ambitendency
3
0
0
0
Grasp reflex
0
0
0
0
Perseveration
0
0
0
0
Combativeness
0
0
0
0
Autonomic abnormality
0
0
0
0
Total
12
6
0
0

Discussion

Over forty different catatonic symptoms have been described to date [2, 7, 12]. These may be subdivided into the following four categories: motor phenomena (stupor, catalepsy, rigidity, flexibilitas cerea), withdrawal (mutism, staring gaze, negativism, refusal to eat and drink), excitement (hyperactivity, combativeness, autonomous instability, undirected potentially dangerous aggression) and odd repetitive behaviour (grimacing echolalia, echopraxia, stereotypies, manierisms, perseveration, command-automatism, Mitmachen and Gegenhalten, and ambitendency) [7, 9, 13].
Catatonia can be divided into four types [5, 7, 13, 14]. There is the hyperkinetic type of catatonia, characterized by agitation, combativeness [15], verbigeration, stereotypies, echolalia and echopraxia. The stuporous type is characterized by stupor, mutism, posturing and negativism. A third type is lethal or malignant catatonia: an often acutely emerged state involving alterations in consciousness, fever, severe rigidity and autonomous instability. The fourth type is periodic catatonia, characterized by the cyclic return of symptoms of catatonia. These episodes last an average of four to 10 days and can return within weeks or years [9].
The differential diagnosis may be challenging given the current lack of biomarkers and symptom aspecificity. The following conditions need to be considered in the differential diagnosis: malignant antipsychotic syndrome, extrapyramidal side effects of psychopharmacological medication, hyperammonemic encephalopathy [16], acute dystonia, tardive dyskinesia, akathisia, manic episodes, delirium, compulsory movement disorders, conversion disorder, certain compulsions in OCD, serotonin syndrome, locked-in syndrome, vegetative state and stiff person syndrome, kinetic disorders with hypocalcemia, tetanus, strychnine toxicity, rabies and complex partial epilepsy, nonconvulsive status epilepticus [2, 4, 9, 1719].
In our differential diagnosis we also considered the following: complex partial epileptic seizures [9, 18, 19], postictal akinesia [20], postictal delirium [19], hypoactive delirium [9], nonconvulsive status epilepticus [4, 9], postictal psychosis [21, 22] and non-psychiatric stupor (characterized by immobility, mutism, absence of response to stimuli; this kind of stupor has other causes than catatonia, such as head trauma, anoxia, epilepsy and encephalopathy of unknown origin) [18].
First we would like to address whether it was an ES and not a psychogenic epileptic seizure (PNES) the patient had suffered from. We could not obtain a video EEG, so there is no certainty since video-EEG is the gold standard for such differentiation. We detected however, after the first and second seizures, the last of which was observed by medical staff, a substantial increase in CK which, according to experts, could be a diagnostic instrument for differentiating between ES and PNES [23, 24]. So there is reason to assume it were ES and not PNES.
Another important distinction that must be made in this case is between postictal delirium (occurring in 35% of seizure cases and reported to last sometimes up to 10 days) [2527] and postictal catatonia as it may substantially influence treatment decision-making [2830]. Whereas benzodiazepines are used first in cases of catatonia, in delirium such compounds may aggravate symptoms [2830]. The distinction between the two may be cumbersome given clinical overlap. According to the DSM-5 it is impossible for the two to co-occur since catatonia cannot be diagnosed in the presence of delirium; others question this notion [30]. In addition, Grover [28] found that 12 to 30% of patients with delirium showed symptoms matching the criteria for catatonia.
Another distinction that has to be made is between postictal catatonia and postictal psychosis [21, 22, 31]. Although psychosis as such can be accompanied by catatonic features, this was not the case here as, firstly, except for the psychomotor symptoms, there were no other symptoms of psychosis. Secondly, postictal psychosis is rarely seen with idiopathic generalized epilepsy [21]. And thirdly, postictal psychosis is mostly characterized by delusions of the grandiose or religious type, aggression, pressured speech and excessive emotional response [31].
In our case a diagnosis of catatonia was considered most plausible based on symptomatology (e.g. lack of day-night differences in symptomatology), absence of adverse effects after the lorazepam ‘challenge test’ and repetitive EEGs showing no signs of epileptic activity. Moreover, our observation that the patient remained well-oriented and attentive argued against delirium and that in combination with the absence of delusions or hallucinations none of the above mentioned characteristics of postictal psychosis were present, against postictal psychosis.
The treatment of catatonia initially consists of benzodiazepines [4, 5, 7, 9, 13, 14, 18, 3235] (effective in 70–80% of all cases) and only when this is ineffective ECT. When ECT is of little help, transcranial magnetic stimulation [18] and NMDA antagonists such as amantadine and memantine [33, 36] may be considered. When these are still ineffective, anticonvulsants can be tried. In some cases, atypical antipsychotics are combined with benzodiazepines [33, 36]. Our patient was treated with valproic acid for epilepsy.
In our case, it was necessary to increase the dose of Lorazepam to 17 mg/d. before we saw clear amelioration of the symptoms. Improvement could in theory also have been attributed to simply time or to the restarted AED since AEDs are also effective in catatonia. But we like to mention that when the AEDs were restarted, the catatonia did not go into remission, and only did so when we augmented the lorazepam to 17 mg/d. Moreover, the fact that the symptoms remained unchanged the first days of occurrence without lorazepam pleads against resolving as a natural course.
The question then arises if ECT would also be a treatment option for our patient. We believe this is since ECT can be given when a patient has a status epilepticus and for catatonia, as mentioned above. There are, to our knowledge, however, no reports of ECT treatment for postictal catatonia.
We searched articles written in Dutch or English in pubmed with the terms ‘post-ictal catatonia’, OR ‘ictal catatonia’ OR ‘catatonia seizures’, OR ‘catatonia postictal state’ OR ‘catatonia and delirium’ as well as cross-references retrieved by our search. We thus found a case series in which four patients developed catatonia during ECT treatment for affective or psychotic disorders [37, 38]. The cause of the catatonia could have been withdrawal of benzodiazepines, besides affective and psychotic disorders, which is supported by the fact that catatonic symptoms disappeared after reinstating benzodiazepines. Two other case reports describe the development of catatonia after ECT, both in patients with a history of bipolar disorder [39, 40], while our patient had no medical history of other psychiatric disorders, except for drug abuse. It is beyond dispute that there is a clear difference between ECT and ES. ECT occurs in a safe environment under controlled circumstances and under narcosis. Furthermore, ECT is often given for conditions that may themselves be accompanied by catatonia. Finally, we found another case report in which catatonia developed postictally, but this patient was known to suffer from schizophrenia [41]. We also found an article by Herman published in 1942 [42], reporting the case of a man stating himself that he suffers from epilepsy. Seizures were, however, not observed and catatonic symptoms were not described clearly.

Conclusion

To our knowledge, we describe the first case of persistent postictal catatonia, following an observed ES. In this case a daily dose of 17 mg of lorazepam was necessary to attain remission. In patients with bradyphrenia and/or remarkable postictal behaviour we advise to consider not only postictal confusion, but catatonia as well, especially when appearing within 24 h after a seizure. Based on our experience we suggest a gradually increasing dose of lorazepam. This dose of medication should be tapered very gradually as rapid tapering may not only spark catatonia relapse, but a new epileptic seizure too.
Bullets:
1.
Catatonia should be considered among those with cognitive and/or movement features that commence postictally.
 
2.
The distinction between delirium and catatonia after an ES may be challenging but has treatment implications.
 
3.
More research into the etiology of catatonia in general and postictal catatonia in particular is highly needed.
 

Acknowledgements

We would like to thank the patient for his collaboration.

Funding

Not applicable.

Availability of data and materials

The data will be shared upon reasonable request.
Not applicable.
Written informed consent was obtained from the patient for the publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Kahlbaum K: Die Katatonie oder das Spannungsirresein; 1874. Kahlbaum K: Die Katatonie oder das Spannungsirresein; 1874.
2.
Zurück zum Zitat Dhossche D. Catatonia in psychiatric illnesses. In: The medical basis of psychiatry. 3rd ed; 2008. p. 455–70.CrossRef Dhossche D. Catatonia in psychiatric illnesses. In: The medical basis of psychiatry. 3rd ed; 2008. p. 455–70.CrossRef
3.
Zurück zum Zitat Dhossche DM, van der Steen LF, Shettar SM. Catatonia in autism spectrum disorders: review and case-report. Tijdschr Psychiatr. 2015;57(2):89–93.PubMed Dhossche DM, van der Steen LF, Shettar SM. Catatonia in autism spectrum disorders: review and case-report. Tijdschr Psychiatr. 2015;57(2):89–93.PubMed
4.
Zurück zum Zitat Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its diagnosis treatment and pathophysiology. World J Psychiatry. 2016;6(4):391–8.CrossRef Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its diagnosis treatment and pathophysiology. World J Psychiatry. 2016;6(4):391–8.CrossRef
5.
Zurück zum Zitat Wijemanne S, Jankovic J. Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015;86(8):825–32.CrossRef Wijemanne S, Jankovic J. Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015;86(8):825–32.CrossRef
6.
Zurück zum Zitat IGG GE, Yosmaoğlu A. Catatonia as a symptom of obsessive compulsive disorder: a case report. Adv Life Sci. 2014;4(5):245–6. IGG GE, Yosmaoğlu A. Catatonia as a symptom of obsessive compulsive disorder: a case report. Adv Life Sci. 2014;4(5):245–6.
7.
Zurück zum Zitat Bruijn DJBJ. Katatonie. nederlands tijdschrift voor geneeskunde. 2010;154:A2284.PubMed Bruijn DJBJ. Katatonie. nederlands tijdschrift voor geneeskunde. 2010;154:A2284.PubMed
8.
Zurück zum Zitat Gelenberg AJ. The catatonic syndrome. Lancet. 1976;1(7973):1339–41.CrossRef Gelenberg AJ. The catatonic syndrome. Lancet. 1976;1(7973):1339–41.CrossRef
9.
Zurück zum Zitat van Harten PN. Katatonie een syndroom om te herinneren. Nederlands tijdschrift voor psychiatrie. 2005;47(6):371–82. van Harten PN. Katatonie een syndroom om te herinneren. Nederlands tijdschrift voor psychiatrie. 2005;47(6):371–82.
10.
Zurück zum Zitat Oldham MA, Desan PH. Alcohol and sedative-hypnotic withdrawal catatonia: two case reports, systematic literature review, and suggestion of a potential relationship with alcohol withdrawal delirium. Psychosomatics. 2016;57(3):246–55.CrossRef Oldham MA, Desan PH. Alcohol and sedative-hypnotic withdrawal catatonia: two case reports, systematic literature review, and suggestion of a potential relationship with alcohol withdrawal delirium. Psychosomatics. 2016;57(3):246–55.CrossRef
11.
Zurück zum Zitat Caudron M, Rolland B, Deheul S, Geoffroy PA, Thomas P, Amad A. Catatonia and cannabis withdrawal: a case report. Subst Abus. 2016;37(1):188–9.CrossRef Caudron M, Rolland B, Deheul S, Geoffroy PA, Thomas P, Amad A. Catatonia and cannabis withdrawal: a case report. Subst Abus. 2016;37(1):188–9.CrossRef
12.
Zurück zum Zitat Sahaya K, Lardizabal D. Catatonia in encephalitis and nonconvulsive seizures: a case report and review of the literature. Epilepsy Behav. 2010;17(3):420–5.CrossRef Sahaya K, Lardizabal D. Catatonia in encephalitis and nonconvulsive seizures: a case report and review of the literature. Epilepsy Behav. 2010;17(3):420–5.CrossRef
13.
Zurück zum Zitat Barnes MP, Saunders M, Walls TJ, Saunders I, Kirk CA. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry. 1986;49(9):991–6.CrossRef Barnes MP, Saunders M, Walls TJ, Saunders I, Kirk CA. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry. 1986;49(9):991–6.CrossRef
14.
15.
Zurück zum Zitat Luykx JJ, Post EH, van der Erf M, Van Hecke J. Agitation after minor trauma: combativeness as a cardinal catatonic feature. BMJ case reports. 2013;2013:bcr2012008217.CrossRef Luykx JJ, Post EH, van der Erf M, Van Hecke J. Agitation after minor trauma: combativeness as a cardinal catatonic feature. BMJ case reports. 2013;2013:bcr2012008217.CrossRef
16.
Zurück zum Zitat Perez-Esparza R, Onate-Cadena N, Ramirez-Bermudez J, Espinola-Nadurille M. Valproate-induced Hyperammonemic encephalopathy presenting as catatonia. Neurologist. 2018;23(2):51–2.CrossRef Perez-Esparza R, Onate-Cadena N, Ramirez-Bermudez J, Espinola-Nadurille M. Valproate-induced Hyperammonemic encephalopathy presenting as catatonia. Neurologist. 2018;23(2):51–2.CrossRef
17.
Zurück zum Zitat Komatsu T, Nomura T, Takami H, Sakamoto S, Mizuno K, Sekii H, Hatta K, Sugita M. Catatonic symptoms appearing before autonomic symptoms help distinguish neuroleptic malignant syndrome from malignant catatonia. Intern Med (Tokyo, Japan). 2016;55(19):2893–7.CrossRef Komatsu T, Nomura T, Takami H, Sakamoto S, Mizuno K, Sekii H, Hatta K, Sugita M. Catatonic symptoms appearing before autonomic symptoms help distinguish neuroleptic malignant syndrome from malignant catatonia. Intern Med (Tokyo, Japan). 2016;55(19):2893–7.CrossRef
18.
Zurück zum Zitat Bartolommei N, Lattanzi L, Callari A, Cosentino L, Luchini F, Mauri M. Catatonia: a critical review and therapeutic recommendations. J Psychopathol. 2012;18:234–46. Bartolommei N, Lattanzi L, Callari A, Cosentino L, Luchini F, Mauri M. Catatonia: a critical review and therapeutic recommendations. J Psychopathol. 2012;18:234–46.
19.
Zurück zum Zitat Repchak AT, Quinn DK. Epileptic catatonia: a case series and systematic review. Psychosomatics. 2016;57(2):217–25.CrossRef Repchak AT, Quinn DK. Epileptic catatonia: a case series and systematic review. Psychosomatics. 2016;57(2):217–25.CrossRef
20.
Zurück zum Zitat Dhossche DM, Sienaert P, van der Heijden FM. Mechanisms of catatonia. Tijdschr Psychiatr. 2015;57(2):99–103.PubMed Dhossche DM, Sienaert P, van der Heijden FM. Mechanisms of catatonia. Tijdschr Psychiatr. 2015;57(2):99–103.PubMed
21.
Zurück zum Zitat Kanner AM, Rivas-Grajales AM. Psychosis of epilepsy: a multifaceted neuropsychiatric disorder. CNS spectrums. 2016;21(3):247–57.CrossRef Kanner AM, Rivas-Grajales AM. Psychosis of epilepsy: a multifaceted neuropsychiatric disorder. CNS spectrums. 2016;21(3):247–57.CrossRef
22.
Zurück zum Zitat Logsdail SJ, Toone BK. Post-ictal psychoses. A clinical and phenomenological description. Br J Psychiatry. 1988;152:246–52.CrossRef Logsdail SJ, Toone BK. Post-ictal psychoses. A clinical and phenomenological description. Br J Psychiatry. 1988;152:246–52.CrossRef
23.
Zurück zum Zitat Nass RD, Sassen R, Elger CE, Surges R. The role of postictal laboratory blood analyses in the diagnosis and prognosis of seizures. Seizure. 2017;47:51–65.CrossRef Nass RD, Sassen R, Elger CE, Surges R. The role of postictal laboratory blood analyses in the diagnosis and prognosis of seizures. Seizure. 2017;47:51–65.CrossRef
24.
Zurück zum Zitat Petramfar P, Yaghoobi E, Nemati R, Asadi-Pooya AA. Serum creatine phosphokinase is helpful in distinguishing generalized tonic-clonic seizures from psychogenic nonepileptic seizures and vasovagal syncope. Epilepsy Behav. 2009;15(3):330–2.CrossRef Petramfar P, Yaghoobi E, Nemati R, Asadi-Pooya AA. Serum creatine phosphokinase is helpful in distinguishing generalized tonic-clonic seizures from psychogenic nonepileptic seizures and vasovagal syncope. Epilepsy Behav. 2009;15(3):330–2.CrossRef
25.
Zurück zum Zitat Ito M. Neuropsychiatric evaluations of postictal behavioral changes. Epilepsy Behav. 2010;19(2):134–7.CrossRef Ito M. Neuropsychiatric evaluations of postictal behavioral changes. Epilepsy Behav. 2010;19(2):134–7.CrossRef
26.
Zurück zum Zitat Krauss G, Theodore WH. Treatment strategies in the postictal state. Epilepsy Behav. 2010;19(2):188–90.CrossRef Krauss G, Theodore WH. Treatment strategies in the postictal state. Epilepsy Behav. 2010;19(2):188–90.CrossRef
27.
Zurück zum Zitat Shorvon S, Trinka E. Nonconvulsive status epilepticus and the postictal state. Epilepsy Behav. 2010;19(2):172–5.CrossRef Shorvon S, Trinka E. Nonconvulsive status epilepticus and the postictal state. Epilepsy Behav. 2010;19(2):172–5.CrossRef
28.
Zurück zum Zitat Grover S, Ghosh A, Ghormode D. Do patients of delirium have catatonic features? An exploratory study. Psychiatry Clin Neurosci. 2014;68(8):644–51.CrossRef Grover S, Ghosh A, Ghormode D. Do patients of delirium have catatonic features? An exploratory study. Psychiatry Clin Neurosci. 2014;68(8):644–51.CrossRef
29.
Zurück zum Zitat Schieveld JNM, Strik J. Catatonia, delirium, and critical illness: a diagnostic statistical manual 5 mystery partially disentangled. Crit Care Med. 2017;45(11):1953–4.CrossRef Schieveld JNM, Strik J. Catatonia, delirium, and critical illness: a diagnostic statistical manual 5 mystery partially disentangled. Crit Care Med. 2017;45(11):1953–4.CrossRef
30.
Zurück zum Zitat Wilson JE, Carlson R, Duggan MC, Pandharipande P, Girard TD, Wang L, Thompson JL, Chandrasekhar R, Francis A, Nicolson SE, et al. Delirium and catatonia in critically ill patients: the delirium and catatonia prospective cohort investigation. Crit Care Med. 2017;45(11):1837–44.CrossRef Wilson JE, Carlson R, Duggan MC, Pandharipande P, Girard TD, Wang L, Thompson JL, Chandrasekhar R, Francis A, Nicolson SE, et al. Delirium and catatonia in critically ill patients: the delirium and catatonia prospective cohort investigation. Crit Care Med. 2017;45(11):1837–44.CrossRef
31.
Zurück zum Zitat Sakakibara E, Nishida T, Sugishita K, Jinde S, Inoue Y, Kasai K. Acute psychosis during the postictal period in a patient with idiopathic generalized epilepsy: postictal psychosis or aggravation of schizophrenia? A case report and review of the literature. Epilepsy Behav. 2012;24(3):373–6.CrossRef Sakakibara E, Nishida T, Sugishita K, Jinde S, Inoue Y, Kasai K. Acute psychosis during the postictal period in a patient with idiopathic generalized epilepsy: postictal psychosis or aggravation of schizophrenia? A case report and review of the literature. Epilepsy Behav. 2012;24(3):373–6.CrossRef
32.
Zurück zum Zitat Honings ST, Arts BM, van Os J. A case-report on catatonia: a prevalent but under-recognised psychiatric illness. Tijdschr Psychiatr. 2016;58(3):232–6.PubMed Honings ST, Arts BM, van Os J. A case-report on catatonia: a prevalent but under-recognised psychiatric illness. Tijdschr Psychiatr. 2016;58(3):232–6.PubMed
33.
Zurück zum Zitat Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G. A clinical review of the treatment of catatonia. Front Psychiatry. 2014;5:181.CrossRef Sienaert P, Dhossche DM, Vancampfort D, De Hert M, Gazdag G. A clinical review of the treatment of catatonia. Front Psychiatry. 2014;5:181.CrossRef
34.
Zurück zum Zitat Walstra AN, den Broek MV, Giltay EJ, van Paassen J, van Noorden MS. Successful amantadine treatment of a patient with ECT-resistant catatonia. Tijdschr Psychiatr. 2016;58(8):599–602.PubMed Walstra AN, den Broek MV, Giltay EJ, van Paassen J, van Noorden MS. Successful amantadine treatment of a patient with ECT-resistant catatonia. Tijdschr Psychiatr. 2016;58(8):599–602.PubMed
35.
Zurück zum Zitat Walther S, Schappi L, Federspiel A, Bohlhalter S, Wiest R, Strik W, Stegmayer K. Resting-state Hyperperfusion of the supplementary motor area in catatonia. Schizophr Bull. 2017;43(5):972–81.CrossRef Walther S, Schappi L, Federspiel A, Bohlhalter S, Wiest R, Strik W, Stegmayer K. Resting-state Hyperperfusion of the supplementary motor area in catatonia. Schizophr Bull. 2017;43(5):972–81.CrossRef
36.
Zurück zum Zitat Beach SR, Gomez-Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: a systematic review. Gen Hosp Psychiatry. 2017;48:1–19.CrossRef Beach SR, Gomez-Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: a systematic review. Gen Hosp Psychiatry. 2017;48:1–19.CrossRef
37.
Zurück zum Zitat Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. World J Psychiatry. 2015;5(2):182–92.CrossRef Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. World J Psychiatry. 2015;5(2):182–92.CrossRef
38.
Zurück zum Zitat Malur C, Francis A. Emergence of catatonia during ECT. J ECT. 2001;17(3):201–4.CrossRef Malur C, Francis A. Emergence of catatonia during ECT. J ECT. 2001;17(3):201–4.CrossRef
40.
Zurück zum Zitat Tan AH, Low SC, Tan CY, Lim KS, Tan CT, Lim SY. “Ictal catatonia”: rare but not to be missed! Parkinsonism Relat Disord. 2016;32:137–9.CrossRef Tan AH, Low SC, Tan CY, Lim KS, Tan CT, Lim SY. “Ictal catatonia”: rare but not to be missed! Parkinsonism Relat Disord. 2016;32:137–9.CrossRef
41.
Zurück zum Zitat Gunduz A, Benbir G, Bayar R. Postictal catatonia in a schizophrenic patient and electroconvulsive treatment. J ECT. 2008;24(2):166–7.CrossRef Gunduz A, Benbir G, Bayar R. Postictal catatonia in a schizophrenic patient and electroconvulsive treatment. J ECT. 2008;24(2):166–7.CrossRef
42.
Zurück zum Zitat Herman M. Nonschizophrenic catatonic states. NY State JM. 1942;1:624–7. Herman M. Nonschizophrenic catatonic states. NY State JM. 1942;1:624–7.
Metadaten
Titel
Persistent catatonia following epileptic seizures: a case report and systematic literature search
verfasst von
Ragnar Verbraeken
Jurjen J. Luykx
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Psychiatry / Ausgabe 1/2018
Elektronische ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1935-0

Weitere Artikel der Ausgabe 1/2018

BMC Psychiatry 1/2018 Zur Ausgabe